Previous Article |
Table of Contents
| Next Article
Hormel Institute, University of Minnesota, Austin, MN 55912
Contributed by Ralph T. Holman, April 20, 2001
Epidemiological and animal-based investigations have indicated that
the development of skin cancer is in part associated with poor dietary
practices. Lipid content and subsequently the derived fatty acid
composition of the diet are believed to play a major role in the
development of tumorigenesis. Omega 3 ( Nonmelanoma skin cancer is
the most common type of cancer in the United States and is presently a
major cause of morbidity and mortality in our society (1). Typically
associated with sun and UV radiation exposure, the development of skin
cancer has also been reported to be related to dietary factors,
including dietary lipids. Epidemiological and experimental studies have shown that different classes of dietary fatty acids have a variety of
effects on tumor development. Specifically, omega 3 ( Transcription factor activator protein 1 (AP-1) is an inducible
eukaryotic transcription factor composed of the products of the
jun and fos oncogene families (12-14). The AP-1
dimers bind to and transactivate promoter regions on DNA that contain
cis-acting phorbol 12-tetradecanoate 13-acetate (TPA) response elements
to induce transcription of genes involved in cell proliferation, metastasis, and cellular metabolism (15). AP-1 is induced by a variety
of stimuli and is implicated in the development of cancer (12).
Agonists, such as TPA and epidermal growth factor (EGF), are two of the
most common agents used to study the experimental induction of AP-1 and
cellular transformation in cellular and animal models of cancer (16).
Several reports have established the role of AP-1 activation in
cellular transformation and tumor promotion. In JB6 mouse epidermal
cell lines, TPA and EGF induce AP-1 transcriptional activity in
promotion-sensitive (P+) phenotypes but not in
promotion-resistant (P In the present study, we investigated the effects of EPA, DHA, and AA
on TPA- or EGF-induced AP-1 transactivation and on subsequent cell
transformation in the JB6 mouse epidermal cell line. This study
provides new insight into the primary mechanisms by which certain
dietary essential fatty acids inhibit or promote tumorigenesis and
support epidemiological reports that suggest that diets rich in Cell Culture and Reagents.
AP-1 luciferase reporter plasmid stably transfected mouse epidermal JB6
P+ 1-1 cells and the JB6 mouse epidermal cell
line, Cl 41, were cultured in monolayers at 37°C, 5%
CO2 by using Eagle's minimal essential medium,
MEM, containing 5% FBS, 2 mM L-glutamine, and 25 µg of gentamicin per ml. FBS and MEM were from BioWhittaker; TPA,
aprotinin, leupeptin, and low-endotoxin albumin (LEA) were from Sigma;
EGF was from Clonetics (San Diego); DHA (C22:6,
4,7,10,13,16,19-docosahexaenoic acids), EPA (C20:5,
5,8,11,14,17-eicosapentaenoic acids), and AA (C20:4,
5,8,11,14-arachidonic acids) were from Nu Chek Prep (Elysian, MN);
luciferase assay substrate was from Promega; specific antibodies
against phosphorylated sites of Erks, p38 kinase, and the c-Jun
NH2-terminal kinase (JNK) assay kit were from New
England Biolabs.
Fatty Acid Preparation.
A 5% LEA solution (16.6 ml) was added to each 10 mg of fatty acid and
mixed with a Vortex mixer. The mixture was then bubbled very slowly
with N2 for 60 s to remove any oxygen and
then incubated in a sealed tube for 4 h at 37°C in a shaking
water bath. The fatty acid/albumin complex (0.6 mg of fatty acid per
ml) solution was then filter-sterilized, divided into aliquots in
single-use vials, and kept frozen at Luciferase Assay for AP-1 Transactivation.
Confluent monolayers of JB6 P+ 1-1 cells were
trypsinized, and 8,000 viable cells suspended in 100 µl of 5% FBS
MEM were added to each well of a 96-well plate. Plates were incubated
at 37°C in a humidified atmosphere of 5%
CO2/95% air. Cells were starved for 24 h
and then treated for another 48 h by culturing them in 0.1% FBS
MEM with different concentrations of the fatty acids indicated. The
cells were then exposed to either TPA (20 ng/ml) or EGF (20 ng/ml).
After 24 h in culture, the cells were extracted with 100 µl of
lysis buffer and luciferase activity was measured by using a
luminometer (Monolight 2010; Analytical Luminescence Laboratory, San
Diego). The results are expressed as relative AP-1 activity (21).
Anchorage-Independent Transformation Assay.
JB6 C1 41 cells (8 × 103 per ml) were
exposed to either TPA or EGF with or without EPA, DHA, or AA at
concentrations ranging from 2.5 to 20 µg/ml in 1 ml of 0.33% basal
medium of Eagle agar containing 10% FBS over 3.5 ml of 0.5% basal
medium Eagle agar containing 10% FBS. Additionally, mixtures of DHA
(20 µg/ml) containing increasing concentrations of AA (from 5 µg/ml to 20 µg/ml) were also tested. The cultures were
maintained in a 37°C, 5% CO2 incubator for 4 weeks. Cell colonies were then scored as described by Colburn et
al. (22). The effects of the fatty acids on cell transformation of
JB6 C1 41 cells are presented as a percentage inhibition of cell
transformation in soft agar compared with TPA- or EGF-stimulated cells.
AP-1 DNA Binding Studies.
Electrophoretic mobility-shift assays were performed essentially as
described (23). Nuclear protein extracts were prepared from JB6 C1 41 cells by the modified method of Monick et al. (24). Briefly,
JB6 C1 41 cells were cultured in 10-cm dishes. After 48 h of
pretreatment with different concentrations of fatty acids as indicated
in low percentage medium (0.1%), the cells were exposed to TPA (20 ng/ml) or EGF (20 ng/ml) and incubated for another 12 h. The
cells were then harvested and disrupted in 500 µl of lysis buffer A
(25 mM Hepes, pH 7.8/50 mM KCl/0.5% Nonidet P-40/100 µM
DTT/10 µg/ml leupeptin/25 µg/ml aprotinin/1 mM PMSF). The
pellet containing the nuclei was washed once with 500 µl of buffer B (buffer A without Nonidet P-40), resuspended in 150 µl of extraction buffer (buffer B but with 500 mM KCl and 10% glycerol), and shaken at
4°C for 30 min. The DNA binding reaction (for the electrophoretic mobility-shift assay) was carried out at room temperature for 30 min in
a mixture containing 4 µg of nuclear protein, 1 µg of poly(dI·dC), and 15,000 cpm of 32P-labeled
double-stranded AP-1 oligonucleotide (5'-CGCTTGATGAGTCAGCCGGAA-3'). The
samples were fractionated through a 5% polyacrylamide gel. Gels were
dried and analyzed by using the Storm 840 Phospho-Image System
(Molecular Dynamics).
JNK Kinase Assay.
JB6 Cl 41 cells were pretreated with the various concentrations of
fatty acids as indicated and starved for 48 h in 0.1% FBS MEM as
described earlier. Cells were then exposed to TPA (20 ng/ml) or EGF
(20 ng/ml) followed by culturing for another 30 min. The JNK kinase
assay was carried out according to the protocol of New England Biolabs
(www.neb.com). c-Jun phosphorylation was selectively measured by
Western immunoblotting by using a specific c-Jun antibody against
phosphorylated c-Jun at serine-63.
Immunoblotting for Phosphorylated Erks and p38 Kinase.
Immunoblotting for the phosphorylated proteins Erks and p38 kinase was
carried out by using specific antibodies against phosphorylated sites
on Erks or p38 kinase (19) according to the supplier's recommendations
(Cell Signaling Technology, Beverly, MA). Antibody-bound proteins were
detected by chemiluminescence and analyzed by using the Storm 840 Phospho-Image System (Molecular Dynamics).
Statistical Analysis.
Significant differences in AP-1 activity were determined by using the
Student's t test. The results are expressed as means ± SD.
Varied Effects of Fatty Acids on AP-1 Activity.
No significant changes were observed in AP-1 activity when stably
transfected mouse epidermal JB6 P+ 1-1 cells were
cultured with EPA, DHA, or AA alone compared with the LEA control (data
not shown). DHA markedly inhibited TPA-induced AP-1 activity (83%,
P < 0.01) from the lowest concentration, 2.5 µg/ml, to the highest concentration of 20 µg/ml (Fig.
1A). Increasing the DHA
concentration had no further inhibitory effect on AP-1 activity induced
by TPA. EPA treatment moderately inhibited TPA-induced AP-1 activity
(48% inhibition at 2.5 µg/ml, P < 0.05; Fig.
1A). DHA treatment also resulted in a significant
inhibition of EGF-induced AP-1 activity in an apparent
concentration-dependent manner, whereas EPA had no effect (Fig.
1B). AA treatment had no effect on either TPA- or
EGF-induced AP-1 activity (Fig. 1). To confirm that the observed
effects were not due to cytotoxicity, we investigated [3H]thymidine incorporation into the cells
under the exact conditions of fatty acid treatment, and no significant
effects on growth inhibition or cellular viability were found (data not
shown).
Medical Sciences
Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and
cell transformation in JB6 cells
![]()
Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
3) fatty acids, including
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), can
effectively reduce the risk of skin cancer whereas omega 6 (
6) fatty
acids such as arachidonic acid (AA) reportedly promote risk. To
investigate the effects of fatty acids on tumorigenesis, we performed
experiments to examine the effects of the
3 fatty acids EPA and DHA
and of the
6 fatty acid AA on phorbol 12-tetradecanoate 13-acetate
(TPA)-induced or epidermal growth factor (EGF)-induced transcription
activator protein 1 (AP-1) transactivation and on the subsequent
cellular transformation in a mouse epidermal JB6 cell model. DHA
treatment resulted in marked inhibition of TPA- and EGF-induced cell
transformation by inhibiting AP-1 transactivation. EPA treatment also
inhibited TPA-induced AP-1 transactivation and cell transformation but
had no effect on EGF-induced transformation. AA treatment had no effect
on either TPA- or EGF-induced AP-1 transactivation or transformation,
but did abrogate the inhibitory effects of DHA on TPA- or EGF-induced
AP-1 transactivation and cell transformation in a dose-dependent
manner. The results of this study demonstrate that the inhibitory
effects of
3 fatty acids on tumorigenesis are more significant for
DHA than for EPA and are related to an inhibition of AP-1. Similarly,
because AA abrogates the beneficial effects of DHA, the dietary ratio
of
6 to
3 fatty acids may be a significant factor in mediating tumor development.
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
3) fatty acids
such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the
nomenclature of which was developed at our institute (2), are
reportedly chemopreventive (3-7) whereas omega 6 (
6) fatty acids,
including linoleic acid (LA) and its in vivo metabolized
product, arachidonic acid (AA), are chemopromotive (8-11).
) phenotypes. Blocking
AP-1 induction causes P+ cells to revert to the
P
phenotype, indicating the unique requirement
for AP-1 activity in TPA- and EGF-induced cell transformation (17).
Moreover, various chemopreventive agents long known to have inhibitory
effects on cell transformation and tumor promotion (e.g., aspirin,
sodium salicylate, and retinoic acid) also suppress AP-1
transactivation (18-20).
3
fatty acids and low in
6 are chemoprotective.
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
70°C.
![]()
Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (44K):
[in a new window]
Fig. 1.
DHA suppresses both TPA- and EGF-induced AP-1 activity, but EPA
suppresses only TPA-induced AP-1 activity. AP-1 luciferase reporter
plasmid stably transfected JB6 P+ 1-1 cells were cultured
and treated as described in Materials and Methods. After
a 48-h treatment with fatty acids at the concentrations indicated, 20 ng/ml TPA or EGF was added and the cells were cultured for another
24 h before harvest. (A) DHA at 2.5 µg/ml
significantly inhibits TPA-induced AP-1 activity (67% inhibition,
P < 0.01; mean ± SD of triplicate
experiments, six wells each); increased concentrations of DHA did not
further inhibit AP-1 activity. EPA inhibited TPA-induced AP-1 activity
in a concentration-dependent manner (P < 0.01;
mean ± SD of triplicate experiments, six wells each). AA failed
to inhibit AP-1 activity at the concentrations indicated
(P > 0.05; mean ± SD of triplicate
experiments, six wells each). (B) DHA inhibited
EGF-induced AP-1 activity in a concentration-dependent manner
(P < 0.01 at 10 or 20 µg/ml; mean ± SD
of triplicate experiments, six wells each). Neither EPA nor AA affected
EGF-induced AP-1 activity (P > 0.05; mean ± SD of triplicate experiments, six wells each).
AA Abrogates the Inhibitory Effect of DHA on TPA-induced AP-1 Activity. Although AA, a direct substrate of cyclooxygenase-2, can be converted to prostglandin E2 (PGE2), which is reported to induce AP-1 activation (25, 26), in our experiments AA did not induce AP-1 activity. To investigate the potential interactive effects of AA and DHA on AP-1 activation, we combined increasing concentrations of AA (Fig. 2) with a fixed amount of DHA (20 µg/ml) that was found to inhibit AP-1 activation in the TPA- or EGF-JB6 model as reported herein. Surprisingly, the DHA inhibitory effect on TPA-induced AP-1 activation was significantly (P < 0.01) abrogated by AA in a concentration-dependent manner (Fig. 2). Similar results were observed in the EGF-stimulated cells, but to a much lesser extent (Fig. 2).
|
DHA Suppresses JB6 Cell Anchorage-Independent Transformation. Cell transformation was determined by a cell anchorage-independent growth assay on soft agar. In the absence of TPA or EGF, no Cl 41 colony formation in soft agar was observed. However, treatment by TPA or EGF promoted significant Cl 41 transformation and colony formation on soft agar. EGF treatment resulted in larger and more robust cell colony formation when compared with cells treated with TPA. DHA significantly repressed TPA- and EGF-induced cell transformation and colony formation on soft agar (Fig. 3 A and B). However, treatment with EPA suppressed TPA-induced cell transformation only at the highest dose (20 µg/ml, Fig. 3A) but had no effect on EGF-induced transformation (Fig. 3B). AA did not significantly effect cell transformation induced by TPA or EGF on soft agar. AA treatment did, however, reduce the inhibitory effects of DHA in both TPA- and EGF-induced cell transformation (Fig. 4). These findings are in agreement with the effects of EPA, DHA, and AA treatment on AP-1 activity as reported herein.
|
|
DHA Represses AP-1 DNA Binding. As a transcription factor, AP-1 mediates gene transcription induced by TPA, growth factors, cytokines, and many other stimuli by binding to the TPA response element site in the promoter region of a specific target gene (27). AP-1 DNA binding activity as an index of activation was therefore measured by electrophoretic mobility-shift assay after pretreatment of cells with EPA, DHA, or AA. Our findings indicated that LEA alone (10 µg/ml) enhanced AP-1 DNA binding (Fig. 5A, lane 3). This result, however, may be due to the positive effects of albumin on cell growth. In comparison to LEA alone and in the absence of an agonist, DHA did not effect AP-1 DNA binding, whereas EPA and AA slightly increased DNA binding of AP-1 (Fig. 5A, lanes 5 and 6). Treatment with TPA (20 ng/ml) resulted in a significant increase in AP-1 DNA binding (Fig. 5A, lane 7). This increased binding could be completely eliminated by adding a 10-fold excess of unlabeled AP-1 oligonucleotide, confirming that the electrophoretic mobility-shift band was specific for AP-1 binding (Fig. 5A, lane 1). DHA (10 µg/ml) treatment inhibited AP-1 DNA binding induced by either TPA or EGF (Fig. 5 B and C). However, EPA had no effect on AP-1 DNA binding.
|
Mitogen-Activated Protein (MAP) Kinases Are Not Involved in Fatty Acid-Mediated AP-1 Activity Induced by TPA or EGF. MAP kinases contribute to the induction of AP-1 activity in response to a broad range of extracellular stimuli (27). In our experiments, both TPA and EGF induced phosphorylation of Erks and p38 kinase (Fig. 6 A and B). Neither TPA nor EGF induced detectable phosphorylation of JNKs as assessed by Western blot analysis (data not shown). TPA and EGF did, however, induce the phosphorylation of a direct substrate of JNKs, c-Jun at serine-63 (Fig. 6 C and D). None of the fatty acids tested, however, affected TPA- or EGF-induced phosphorylation of any of the MAP kinases measured (Fig. 6).
|
| |
Discussion |
|---|
|
|
|---|
Epidemiological studies have suggested that
3 fatty acids, such
as DHA and EPA, are effective chemopreventive agents (13, 28-30). In
animal experiments, fish oil, rich in the long-chain
3 fatty acids
EPA and DHA, significantly suppressed the incidence of colon cancer and
average tumor volume (31). In contrast, maintaining animals on diets
high in
6 fatty acids, such as LA from vegetable oil, significantly
increased cancer incidence (31). In hairless mice, 2 weeks of fish oil
feeding resulted in a significant reduction in the inflammatory
response in skin and increased skin repair after ultraviolet A
exposure, compared with animals raised on corn oil high in LA (32). In
mice, the photocarcinogenic response increased with increasing amounts
of LA in the diet, compared with a diet high in saturated fat (33).
These results agreed with data from other groups that reported that
diets high in
6 fatty acids, such as LA or AA, significantly
elevated risk of developing cancer (34-37). In the present study, we
report that DHA significantly inhibits TPA- or EGF-induced cell
transformation in a mouse epidermal JB6 cell model. Based on the
findings that DHA suppresses TPA- and EGF-induced AP-1 DNA binding and
AP-1 transactivation, we hypothesize that the inhibitory effects of DHA
on cancer development are due, at least in part, to the suppression of
AP-1 activity. EPA, however, was not as effective as DHA in suppressing
AP-1 transactivation, a result that may argue against an
eicosanoid-mediated event. Topical treatment with EPA, however, was
reported to protect against ultraviolet B-induced damage by preventing
immunosuppression (38). In the present study, when AA was tested no
direct induction of AP-1 activity was observed. AA treatment in
conjunction with DHA, however, strongly abrogated the DHA-mediated
inhibition of AP-1 activity. In addition, the effects of fatty acids on
AP-1 transactivation are consistent with their observed effects on cell
transformation in soft agar anchorage-independent colony formation,
further demonstrating that the reported cell transformation effects are
due to interaction with AP-1.
The precise mechanisms that explain the effects of various fatty acids
on tumor development are largely unclear. Epidermal cells lack
6 desaturase activity, which is the
rate-limiting enzyme for the conversion of LA into AA and
-linolenic
acid into DHA. In addition, many unique eicosanoid and lipoxygenase
metabolites are present in the skin, where they may also play a central
role in cell signaling related to skin cancer development (39). The
role that diet and, specifically, fatty acids play in
photocarcinogenesis remains largely unknown but is reportedly related
to eicosanoid signaling, peroxidation effects, and modulation of the
immune system (40). Other suggestions include an eicosanoid-mediated
mechanism whereby formation of PGE2, a major
prostaglandin of the mammalian epidermis derived from AA, is either
stimulated or inhibited by
3 or
6 fatty acids (41).
Cyclooxygenase-2 activity and PGE2 are reportedly involved in tumor development (42, 43). Increased proportions of AA in
cellular membrane lipids (the eicosanoid precursor pool), resulting
from diets high in
6 and low in
3, provide an increased PGE2 level. EPA and DHA compete with AA and thus
strongly inhibit the formation of PGE2 from AA
(44-46). Several studies (47-49) have suggested that
PGE2 is signaling through AP-1 and thus may play a definitive role in tumor development. Additionally, the significance of eicosanoids in mediation of skin cancer development has been demonstrated by the inhibition of photocarcinogenesis in the hairless mouse treated with the cyclooxygenase inhibitor indomethacin (50). These observations may explain the effects of fatty acids on tumor development. Moreover, the different effects of EPA and DHA on AP-1
transactivation observed in our experiments may be related to their
differential effects on tumor suppression.
Many mechanisms are involved in the up- and down-regulation of AP-1 activity (12). MAP kinases are the most common signaling pathways known to mediate AP-1 function (27), and the blocking of MAP kinases leads to the inhibition of AP-1 transactivation and subsequent cell transformation (51-57). In the present study, however, we found no effect of EPA, DHA, or AA on TPA- or EGF-induced activation of JNKs, Erks, or p38 kinases, the three members of the MAP kinase family. These results indicate that the effects of EPA and DHA on AP-1 activity may not be mediated by MAP kinase pathways, but rather by other mechanisms (27).
In summary, our data showed that
3 fatty acids efficiently inhibit
tumor promoter-induced AP-1 transactivation and subsequent cell
transformation in mouse epidermal JB6 cells. DHA was a more efficient
inhibitor than EPA. The
6 fatty acid, AA, had no effect on AP-1
activity but abrogated the inhibitory effects of DHA on tumor
promoter-induced AP-1 activity and subsequent cell transformation. We
conclude that signaling to AP-1 is involved in the observed effects of
EPA, DHA and AA on tumor development.
| |
Acknowledgements |
|---|
We thank Ms. Andria Hansen for her secretarial assistance and review. This work was supported by The Hormel Foundation and by National Institutes of Health Grants CA 77646, CA 81064, and CA 74916
| |
Abbreviations |
|---|
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; AA, arachidonic acid; AP-1, activator protein 1; TPA, phorbol 12-tetradecanoate 13-acetate; EGF, epidermal growth factor; LEA, low-endotoxin albumin; JNK, cJun NH2-terminal kinase; MAP, mitogen-activated kinase; PGE2, prostaglandin E2.
| |
Footnotes |
|---|
* To whom reprint requests should be addressed at: Hormel Institute, University of Minnesota, 801 16th Avenue NE, Austin, MN 55912. E-mail: zgdong{at}smig.net.
| |
References |
|---|
|
|
|---|
| 1. | Miller, D. L. & Weinstock, M. A. (1994) J. Am. Acad. Dermatol. 30, 774-778[ISI][Medline] . |
| 2. | Holman, R. T. & Mohrhauer, H. (1963) Acta Chem. Scand. 17, S84-S90. |
| 3. | Yen, A. , Black, H. S. & Tschen, J. (1994) Arch. Dermatol. Res. 286, 331-336[Medline] . |
| 4. |
Potter, J. D.
, Slattery, M. L.
, Bostick, R. M.
& Gapstur, S. M.
(1993)
Epidemiol. Rev.
15,
499-545 |
| 5. | Reddy, B. S. (1994) Cancer Metastasis Rev. 13, 285-302[CrossRef][ISI][Medline] . |
| 6. |
Parkinson, A. J.
, Cruz, A. L.
, Heyward, W. L.
, Bulkow, L. R.
, Hall, D.
, Barstaed, L.
& Connor, W. E.
(1994)
Am. J. Clin. Nutr.
59,
384-388 |
| 7. | Caygill, C. P. J. , Charlett, A. & Hill, M. J. (1996) Br. J. Cancer 74, 159-164[ISI][Medline] . |
| 8. |
Hillyard, L. A.
& Abraham, S.
(1979)
Cancer Res.
39,
4430-4437 |
| 9. |
Sauer, L. A.
, Dauchy, R. T.
& Blask, D. E.
(2000)
Cancer Res.
60,
5289-5295 |
| 10. | Rose, D. P. & Connolly, J. M. (1999) Pharmacol. Ther. 83, 217-244[CrossRef][ISI][Medline] . |
| 11. |
Rose, D. P.
(1997)
Am. J. Clin. Nutr.
66,
998S-1003S |
| 12. | Angel, P. & Karin, M. (1991) Biochim. Biophys. Acta 1072, 129-157[Medline] . |
| 13. | Orengo, I. F. , Black, H. S. , Kettler, A. H. & Wolf, J. E., Jr. (1989) Photochem. Photobiol. 49, 71-77[ISI][Medline] . |
| 14. | Curran, T. & Franza, B. R., Jr. (1988) Cell 55, 395-397[CrossRef][ISI][Medline] . |
| 15. | Angel, P. , Imagawa, M. , Chiu, R. , Stein, B. , Imbra, R. J. , Rahmsdorf, H. J. , Jonat, C. , Herrlich, P. & Karin, M. (1987) Cell 49, 729-739[CrossRef][ISI][Medline] . |
| 16. | Hunter, T. & Karin, M. (1992) Cell 70, 375-387[CrossRef][ISI][Medline] . |
| 17. |
Dong, Z.
, Birrer, M. J.
, Watts, R. G.
, Matrisian, L. M.
& Colburn, N. H.
(1994)
Proc. Natl. Acad. Sci. USA
91,
609-613 |
| 18. |
Dong, Z.
, Huang, C.
, Brown, R. E.
& Ma, W.-Y.
(1997)
J. Biol. Chem.
272,
9962-9970 |
| 19. |
Huang, C.
, Ma, W-Y.
, Hanenberger, D.
, Cleary, M. P.
, Bowden, G. T.
& Dong, Z.
(1997)
J. Biol. Chem.
272,
26325-26331 |
| 20. |
Agadir, A.
, Chen, G.
, Bost, F.
, Li, Y.
, Mercola, D.
& Zhang, X.
(1999)
J. Biol. Chem.
274,
29779-29785 |
| 21. |
Ding, M.
, Shi, X.
, Dong, Z.
, Chen, F.
, Lu, Y.
, Castranova, V.
& Vallyathan, V.
(1999)
J. Biol. Chem.
274,
30611-30616 |
| 22. |
Colburn, N. H.
, Wendel, E. J.
& Abruzzo, G.
(1981)
Proc. Natl. Acad. Sci. USA
78,
6912-6916 |
| 23. | Rosenberger, S. F. & Bowden, G. T. (1996) Oncogene 12, 2301-2308[ISI][Medline] . |
| 24. |
Monick, M. M.
, Carter, A. B.
& Hunninghake, G. W.
(1999)
J. Biol. Chem.
274,
18075-18080 |
| 25. | Chen, Y. & Hughes-Fulford, M. (2000) Br. J. Cancer 82, 2000-2006[CrossRef][ISI][Medline] . |
| 26. | Simonson, M. S. , Herman, W. H. & Dunn, M. J. (1994) Exp. Cell Res. 215, 137-144[CrossRef][ISI][Medline] . |
| 27. |
Karin, M.
(1995)
J. Biol. Chem.
270,
16483-16486 |
| 28. | Branden, L. M. & Carroll, K. K. (1986) Lipids 21, 285-286[CrossRef][ISI][Medline] . |
| 29. | Steinmetz, K. A. & Potter, J. D. (1991) Cancer Causes Control 2, 325-357[CrossRef][ISI][Medline] . |
| 30. | Hakim, I. A. , Harris, R. B. & Ritenbaugh, C. (2000) Nutr. Cancer 36, 155-162[CrossRef][ISI][Medline] . |
| 31. | Zhou, S. , Wang, G. , Chen, B. & Wang, P. (2000) J. Environ. Pathol. Toxicol. Oncol. 19, 81-86[Medline] . |
| 32. | Yen, A. , Black, H. S & Tschen, J. (1994) Arch. Dermatol. Res. 286, 331-336. |
| 33. | Reeve, V. E , Bosnic, M. & Boehmwilcox, C. (1996) Cancer Lett. 108, 271-279[CrossRef][ISI][Medline] . |
| 34. |
de Lorgeril, M.
, Salen, P.
, Martin, J.-L.
, Monjaud, I.
, Boucher, P.
& Mamelle, N.
(1998)
Arch. Intern. Med.
158,
1181-1187 |
| 35. | Willet, W. C. , Sacks, F. , Trichopoulou, A. , Drescher, G. , Ferro-Luzzi, A. , Helsing, E. & Trichopoulos, D. (1995) Am. J. Clin. Nutr. 61, 1402S-1406S[Abstract]. |
| 36. | Holman, R. T. (1998) J. Nutr. 128, 427S-433S. |
| 37. | Okuyama, H. , Kabayashi, T. & Watanabe, S. (1997) Prog. Lipid Res. 35, 409-457. |
| 38. | Moison, R. M. W. , Steenvoorden, D. P. T. & van Henegouwen, G. M. J. B. (2001) Photochem. Photobiol. 73, 64-70[Medline] . |
| 39. |
Ziboh, V. A.
, Miller, C. C.
& Cho, Y. H.
(2000)
Am. J. Clin. Nutr.
71, Suppl. 1,
361S-366S |
| 40. | Ley, R. D & Reeve, V. E. (1997) Environ. Health Perspect. 105,Suppl., 981-984. |
| 41. | Greeves, M. W. & McDonald-Gibson, W. (1972) Br. J. Pharmacol. 46, 172-175[ISI][Medline] . |
| 42. |
Attiga, F. A.
, Fernandez, P. M.
, Weeraratna, A. T.
, Manyak, M. J.
& Patierno, S. R.
(2000)
Cancer Res.
60,
4629-4637 |
| 43. | Liu, X. H. , Kirschenbaum, A. , Yao, S. , Stearns, M. E. , Holland, J. F. , Claffey, K. & Levine, A. C. (1999) Clin. Exp. Metastasis 17, 687-694[CrossRef][ISI][Medline] . |
| 44. | Lands, W. E. M. , LeTellier, P. R. , Rome, L. H. & Vanderhoek, J. Y. (1973) Adv. Biosci. 9, 15-28. |
| 45. | Hamberg, M. (1980) Biochim. Biophys. Acta 618, 389-398[Medline] . |
| 46. | Needleman, P. , Sprecher, H. , Whitaker, H. O. & Wyche, A. (1980) Adv. Prostaglandin Thromboxane Res. 6, 61-68[Medline] . |
| 47. | Simonson, M. S. , Herman, W. H. & Dunn, M. J. (1994) Exp. Cell Res. 215, 137-144. |
| 48. |
Dendorfer, U.
, Oettgen, P.
& Libermann, T. A.
(1994)
Mol. Cell Biol.
14,
4443-4454 |
| 49. | Won, J. S. , Suh, H. W. , Kim, Y. H. , Song, D. K. , Huh, S. O. , Lee, J. K. & Lee, K. J. (1998) Mol. Brain Res. 60, 203-214[Medline] . |
| 50. | Reeve, V. E. , Matheson, M. J. , Bosnic, M. & Boehmwilcox, C. (1995) Cancer Lett. 95, 213-219[CrossRef][ISI][Medline] . |
| 51. |
Dong, Z.
, Ma, W.
, Huang, C.
& Yang, C. S.
(1997)
Cancer Res.
57,
4414-4419 |
| 52. |
Bost, F.
, McKay, R.
, Dean, N.
& Mercola, D.
(1997)
J. Biol. Chem.
272,
33422-33429 |
| 53. | Behrens, A. , Jochum, W. , Sibilia, M. & Wagner, E. F. (2000) Oncogene 19, 2657-2663[CrossRef][ISI][Medline] . |
| 54. |
Monno, S.
, Newman, M. V.
, Cook, M.
& Lowe, W. L., Jr.
(2000)
Endocrinology
144,
544-550 |
| 55. | Tchou, W. W. , Yie, T. A. , Tan, T. H. , Rom, W. N. & Tchou-Wong, K. M. (1999) Oncogene 18, 6974-6980[CrossRef][Medline] . |
| 56. |
Huang, C.
, Li, J.
, Ma, W.-Y.
& Dong, Z.
(1999)
J. Biol. Chem.
274,
29672-29676 |
| 57. |
Pang, L.
, Sawada, T.
, Decker, S. J.
& Saltiel, A. R.
(1995)
J. Biol. Chem.
270,
13585-13588 |
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
H.-G. Kim, K. W. Lee, Y.-Y. Cho, N. J. Kang, S.-M. Oh, A. M. Bode, and Z. Dong Mitogen- and Stress-Activated Kinase 1-Mediated Histone H3 Phosphorylation Is Crucial for Cell Transformation Cancer Res., April 1, 2008; 68(7): 2538 - 2547. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Szymczak, M. Murray, and N. Petrovic Modulation of angiogenesis by {omega}-3 polyunsaturated fatty acids is mediated by cyclooxygenases Blood, April 1, 2008; 111(7): 3514 - 3521. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Morales, M. Porta, J. Vioque, T. Lopez, M. A Mendez, J. Pumarega, N. Malats, M. Crous-Bou, J. Ngo, J. Rifa, et al. Food and nutrient intakes and K-ras mutations in exocrine pancreatic cancer J. Epidemiol. Community Health, July 1, 2007; 61(7): 641 - 649. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Liu, W. Ding, J. Neiman, and K. M. Mulder Requirement of Smad3 and CREB-1 in Mediating Transforming Growth Factor-beta (TGFbeta) Induction of TGFbeta3 Secretion J. Biol. Chem., October 6, 2006; 281(40): 29479 - 29490. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tatsumi, Y.-Y. Cho, Z. He, H. Mizuno, H. Seok Choi, A. M. Bode, and Z. Dong Involvement of the Paxillin Pathway in JB6 Cl41 Cell Transformation Cancer Res., June 1, 2006; 66(11): 5968 - 5974. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Kim, S. Cho, S. Lee, K. H. Kim, K. H. Cho, H. C. Eun, and J. H. Chung Photoprotective and anti-skin-aging effects of eicosapentaenoic acid in human skin in vivo J. Lipid Res., May 1, 2006; 47(5): 921 - 930. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Takahashi, K. Okumura, T. Asai, T. Hirai, H. Murakami, R. Murakami, Y. Numaguchi, H. Matsui, M. Ito, and T. Murohara Dietary fish oil attenuates cardiac hypertrophy in lipotoxic cardiomyopathy due to systemic carnitine deficiency Cardiovasc Res, November 1, 2005; 68(2): 213 - 223. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Kim, C. M. Shin, C.-H. Park, K. H. Kim, K. H. Cho, H. C. Eun, and J. H. Chung Eicosapentaenoic acid inhibits UV-induced MMP-1 expression in human dermal fibroblasts J. Lipid Res., August 1, 2005; 46(8): 1712 - 1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Hardman (n-3) Fatty Acids and Cancer Therapy J. Nutr., December 1, 2004; 134(12): 3427S - 3430S. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Jho, S. M. Cole, E. M. Lee, and N. J. Espat Role of Omega-3 Fatty Acid Supplementation in Inflammation and Malignancy Integr Cancer Ther, June 1, 2004; 3(2): 98 - 111. [Abstract] [PDF] |
||||
![]() |
C. Ma, J. Wang, and J. Luo Exposure to Asphalt Fumes Activates Activator Protein-1 through the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway in Mouse Epidermal Cells J. Biol. Chem., November 7, 2003; 278(45): 44265 - 44272. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. He, Y.-Y. Cho, G. Liu, W.-Y. Ma, A. M. Bode, and Z. Dong p38 Mitogen-activated Protein Kinase Regulation of JB6 Cl41 Cell Transformation Promoted by Epidermal Growth Factor J. Biol. Chem., July 11, 2003; 278(29): 26435 - 26442. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Lee, A. Plakidas, W. H. Lee, A. Heikkinen, P. Chanmugam, G. Bray, and D. H. Hwang Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids J. Lipid Res., March 1, 2003; 44(3): 479 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Liu, W.-Y. Ma, A. M. Bode, Y. Zhang, and Z. Dong NS-398 and Piroxicam Suppress UVB-induced Activator Protein 1 Activity by Mechanisms Independent of Cyclooxygenase-2 J. Biol. Chem., January 17, 2003; 278(4): 2124 - 2130. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Hardman Omega-3 Fatty Acids to Augment Cancer Therapy J. Nutr., November 1, 2002; 132(11): 3508S - 3512. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. de Pablo, M. A. Puertollano, and G. Alvarez de Cienfuegos Biological and Clinical Significance of Lipids as Modulators of Immune System Functions Clin. Vaccine Immunol., September 1, 2002; 9(5): 945 - 950. [Full Text] [PDF] |
||||
| |||||||